Takeda Partners with Asian Hospital to Expand Access to Rare Disease Treatments in Philippines
核心洞察
Takeda Healthcare Philippines (搜索) signed a memorandum of understanding with Asian Hospital and Medical Center (搜索) to broaden patient access to innovative medicines for rare blood cancers and gastrointestinal conditions.
The partnership will provide cost-sharing financial assistance for patients with Hodgkin lymphoma (搜索), multiple myeloma (搜索), and inflammatory bowel disease (搜索) through Takeda's patient assistance programs.
The collaboration addresses significant healthcare gaps in the Philippines, where Hodgkin lymphoma (搜索) ranked 23rd among diagnosed cancers with 602 new cases in 2022 and multiple myeloma (搜索) ranked 21st with 931 cases.
Takeda Healthcare Philippines (搜索) has formalized a strategic partnership with Asian Hospital and Medical Center (搜索) (AHMC) to expand access to life-saving medications for patients with rare blood cancers and gastrointestinal conditions. The memorandum of understanding, signed in Muntinlupa, represents a significant step toward addressing healthcare accessibility challenges faced by Filipino patients.
Partnership Details and Coverage
The collaboration will extend Takeda's patient assistance programs to AHMC patients, specifically targeting rare blood cancers including Hodgkin lymphoma (搜索) and multiple myeloma (搜索), as well as inflammatory bowel disease (搜索) (IBD). The program utilizes innovative financing models where prescribed therapies are provided through a financial eligibility-based, cost-sharing system developed in partnership with healthcare providers.
"Access to life-saving medications should never be about a patient's ability to pay," said Loreann Villanueva, Takeda Philippines Country Manager. "Patients with rare conditions deserve not just our attention, but our unwavering support."
The signing ceremony included key stakeholders from both organizations: Villanueva, Dr. Beaver Tamesis (AHMC President and CEO), Dr. Corazon Ngelangel (Clinical Director of the Asian Cancer Institute at AHMC), and other senior executives from both institutions.
Addressing Healthcare Gaps in the Philippines
Dr. Tamesis emphasized the clinical relevance of the partnership, noting that cases covered under the program are more prevalent than commonly perceived. "There are quite a number of patients, and it's really important that these pharmaceutical products be made available," he stated.
The partnership addresses significant disease burden statistics in the Philippines. According to the Global Cancer Observatory of the World Health Organization's International Agency for Research on Cancer, Hodgkin lymphoma (搜索) ranked 23rd among the most frequently diagnosed cancers in the Philippines, with 602 new cases in 2022. Multiple myeloma (搜索) ranked 21st with 931 new cases.
Gastrointestinal cancers represent an even larger burden, with colorectal cancer (搜索) ranking third among the most prevalent cancers with 20,736 cases, and liver cancer (搜索) ranking fourth with 12,544 new cases. While national statistics on IBD in the Philippines are currently unavailable, the World Journal of Gastroenterology reports approximately 4.9 million people living with IBD globally as of 2019, with regional forecasts suggesting growth in the coming years.
Global Context and Impact
Christina Liza Sta. Maria, AHMC Associate Director for Pharmacy, Healthcare Access, Vaccination, and Nutrition Services, highlighted the broader implications of the partnership. "Cancer is not only a disease—it is a reality that touches families, communities, and health systems," she said. "Through this partnership, we are shaping a future where cancer care is inclusive, responsive, and truly centered on the patient."
The initiative addresses a critical global healthcare challenge, as approximately 2 billion people living in low- and middle-income countries currently lack access to essential medicines. This gap is compounded by ongoing challenges related to healthcare infrastructure and limitations in screening, diagnostics, and treatment availability.
Expanding Network of Care
Takeda's Access to Medicines program reflects the company's global commitment to healthcare equity through sustainable partnerships aligned with national priorities and local community needs. Beyond providing affordable pricing for life-saving drugs, the program advocates for policy changes in areas facing complex healthcare challenges.
The AHMC partnership expands Takeda Philippines' existing network, which already includes collaborations with Makati Medical Center and Healthway Cancer Care Hospital (搜索). This growing network of partnerships strengthens the company's ability to address critical healthcare gaps for Filipino patients across multiple healthcare institutions.
The collaborative approach ensures that support is brought closer to where patients receive care, helping reduce out-of-pocket costs for eligible patients and ensuring that quality treatment becomes accessible regardless of financial circumstances.